Evidence map›Paper›PMID 27604324›Full record

ArticleHuman gene therapy methods2016

A Partial E3 Deletion in Replication-Defective Adenoviral Vectors Allows for Stable Expression of Potentially Toxic Transgene Products.

Larissa H Haut, Amanda L Gill, Raj K Kurupati, Ang Bian, Yan Li, Wynetta Giles-Davis, Zhiquan Xiang, Xiang Yang Zhou, Hildegund C J Ertl

Erratum issuedOpen access · greenAbstract read
In one paragraph

Article in Human gene therapy methods, 2016. The graph could read no effect estimate from its abstract, so it casts no vote on the map. An erratum has been issued. Cited by 3 papers.

0numbers the graph read from it
0cells of the map it votes in
3citing papers in PubMed
0.6field-weighted citation impact, top 21% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

3 citing papers in PubMed, 3 citations in OpenAlex.

  1. Article
  2. Article
  3. Article
4 · The record

Corrections and comments

5 · Who and what money

Authors and funding

9 authors at 1 institution in 1 country.

Larissa H Haut1 The Wistar Institute , Philadelphia, Pennsylvania.
Amanda L Gill1 The Wistar Institute , Philadelphia, Pennsylvania.
Raj K Kurupati1 The Wistar Institute , Philadelphia, Pennsylvania.
Ang Bian1 The Wistar Institute , Philadelphia, Pennsylvania.
Yan Li1 The Wistar Institute , Philadelphia, Pennsylvania.
Wynetta Giles-Davis1 The Wistar Institute , Philadelphia, Pennsylvania.
Zhiquan Xiang1 The Wistar Institute , Philadelphia, Pennsylvania.
Xiang Yang Zhou1 The Wistar Institute , Philadelphia, Pennsylvania.
Hildegund C J Ertl1 The Wistar Institute , Philadelphia, Pennsylvania.
The Wistar Institute · US

Funding

Tumor Microenvironment and MetastasisP30CA010815 · NCI · WISTAR INSTITUTE · PI Luis J Montaner · 1985 to 2026
$75.9M
NCI NIH HHS P30 CA010815
6 · The paper itself

Abstract

Adenovirus (Ad) is used extensively for construction of viral vectors, most commonly with deletion in its E1 and/or E3 genomic regions. Previously, our attempts to insert envelope proteins (Env) of HIV-1 into such vectors based on chimpanzee-derived Ad (AdC) viruses were thwarted. Here, we describe that genetic instability of an E1- and E3-deleted AdC vector of serotype C6 expressing Env of HIV-1 can be overcome by reinsertion of E3 sequences with anti-apoptotic activities. This partial E3 deletion presumably delays premature death of HEK-293 packaging cell lines due to Env-induced cell apoptosis. The same partial E3 deletion also allows for the generation of stable glycoprotein 140 (gp140)- and gp160-expressing Ad vectors based on AdC7, a distinct AdC serotype. Env-expressing AdC vectors containing the partial E3 deletion are genetically stable upon serial cell culture passaging, produce yields comparable to those of other AdC vectors, and induce transgene product-specific antibody responses in mice. A partial E3 deletion thereby allows expansion of the repertoire of transgenes that can be expressed by Ad vectors.

Indexed as

Genetic TherapyAdenoviridaeAnimalsenv Gene Products, Human Immunodeficiency VirusGenetic VectorsHEK293 CellsHIV-1HumansMiceSerogroupTransgenesVirus Replicationenv Gene Products, Human Immunodeficiency Virusgenetic stabilityHIV-1immune responsesvaccine

Identifiers

PMID27604324
PMCPMC5069709
OpenAlexW2508490597

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.